A controlled study has added nail changes to the growing list of concerns being monitored in people taking GLP-1 receptor agonists. Researchers reported that GLP-1 therapies were linked to increased rates of nail detachment, signaling clinicians may need to broaden safety conversations beyond nausea, reflux, and muscle loss. The finding arrives as the commercial footprint of GLP-1 medicines expands across diabetes and weight-management indications, increasing the importance of adverse-event surveillance in larger real-world populations. For dermatology and primary care teams, nail assessments could become a more routine part of adverse-event screening. Regulatory and payer stakeholders may also face pressure to incorporate these outcomes into pharmacovigilance plans and patient counseling guidance.